SOD1, TDP-43, and FUS pathology may converge on impaired iron buffering in motor neurons and glia, increasing labile iron that catalyzes lipid peroxide propagation. Biomarker-guided iron buffering should benefit only the subgroup with demonstrable iron and lipid-peroxidation elevation.
No AI visual card yet
Curated Mechanism Pathway
Curated pathway diagram from expert analysis
flowchart TD
A["SOD1 pathology"]
B["TDP-43 pathology"]
C["FUS pathology"]
D["FTL dysfunction"]
E["Impaired iron buffering in motor neurons and glia"]
F["Labile iron pool expansion"]
G["Catalysis of lipid peroxide propagation"]
H["Lipid peroxidation accumulation"]
I["Ferroptosis"]
J["Motor neuron death"]
K["Biomarker-guided patient stratification"]
L["Identification of iron-elevated subgroup"]
M["Iron chelation therapy"]
N["Reduced labile iron"]
O["Neuroprotection"]
A -->|"converges"| D
B -->|"converges"| D
C -->|"converges"| D
D -->|"causes"| E
E -->|"enables"| F
F -->|"drives"| G
G -->|"propagates"| H
H -->|"induces"| I
I -->|"results in"| J
K -->|"identifies"| L
L -->|"enables targeted"| M
M -->|"reduces"| N
N -->|"prevents"| G
M -->|"provides"| O
J -->|"disease progression"| P["ALS phenotype"]
P -->|"clinical outcome"| Q["Neurological deficit"]
style A fill:#ef5350
style B fill:#ef5350
style C fill:#ef5350
style D fill:#ef5350
style E fill:#ef5350
style F fill:#ef5350
style G fill:#4fc3f7
style H fill:#ef5350
style I fill:#ef5350
style J fill:#ef5350
style K fill:#81c784
style L fill:#81c784
style M fill:#81c784
style N fill:#81c784
style O fill:#ffd54f
Dimension Scores
How to read this chart:
Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential.
The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength),
green shows moderate-weight factors (safety, competition), and
yellow shows supporting dimensions (data availability, reproducibility).
Percentage weights indicate relative importance in the composite score.
5 citations3 with PMIDValidation: 58%3 supporting / 2 opposing
✓For(3)
No supporting evidence
No opposing evidence
(2)Against✗
HighMediumLow
HighMediumLow
Evidence Matrix — sortable by strength/year, click Abstract to expand
Evidence Types
4
1
MECH 4CLIN 0GENE 1EPID 0
Claim
Stance
Category
Source
Strength ↕
Year ↕
Quality ↕
PMIDs
Abstract
No claim
Supporting
MECH
ALS studies rep…
-
-
-
-
-
Inhibition of keratinocyte ferroptosis suppresses …
Multi-persona evaluation:
This hypothesis was debated by AI agents with complementary expertise.
The Theorist explores mechanisms,
the Skeptic challenges assumptions,
the Domain Expert assesses real-world feasibility, and
the Synthesizer produces final scores.
Expand each card to see their arguments.
Gap Analysis | 4 rounds | 2026-04-26 | View Analysis
🧬TheoristProposes novel mechanisms and generates creative hypotheses▼
Three mechanisms deserve priority: loss of GPX4 reserve in stressed motor neurons, ACSL4/LPCAT3-driven enrichment of oxidizable PUFA phospholipids, and genotype-specific iron mishandling in SOD1/TDP-43/FUS disease states. Each is testable with lipidomics plus ferroptosis-rescue controls.
🔍SkepticIdentifies weaknesses, alternative explanations, and methodological concerns▼
The key weakness is causal ordering. Lipid peroxidation appears in many dying neurons, so experiments must show that ferroptosis blockade rescues motor-neuron survival after controlling for apoptosis, necroptosis, mitochondrial collapse, and inflammatory toxicity.
🎯Domain ExpertAssesses practical feasibility, druggability, and clinical translation▼
Translation requires biomarkers before treatment trials: CSF/plasma 4-HNE, F2-isoprostanes, oxidized PE species, GPX4 activity, and iron MRI should stratify patients. Deferiprone-like strategies need careful anemia and mitochondrial safety monitoring.
⚖SynthesizerIntegrates perspectives and produces final ranked assessments▼
Ranked synthesis: prioritize GPX4 reserve failure, then PUFA-phospholipid substrate loading, then labile iron pool expansion. The program should demand orthogonal death-pathway exclusion and genotype-aware rescue studies.